Table 3.

Features of the 11 patients with locoregional recurrence

Characteristics	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11
Age	51	34	49	24	53	45	69	62	81	60	48
Sex	Male	Female	Male	Female	Male	Female	Female	Female	Female	Female	Female
EIN radiation	No	No	No	No	No	No	No	Yes	No	No	No
Clinical stage	T4bN +	T4bN +	T4bN +	T4bN2	T4bN2	T4bN2	T4bN +	T4bN +	T4bN +	T4bN +	T4bN +
Anterior organ involvement	Seminal vesicle	Vagina	Prostate	Uterus	Prostate	Uterus	Uterus	Uterus	Uterus	Uterus	Vagina
Tumor location (cm)	4	4.5	4.2	10.1	2.8	9.1	4.18	5.2	10	6	3.58
Concurrent chemotherapy	XELOX	Capecitabine	Capecitabine	XELOX	XELOX	No	Capecitabine	Capecitabine	Capecitabine	Capecitabine	Capecitabine
Surgery	LAR	LAR	LAR	LAR	Local excision	LAR	MVR	LAR	LAR	MVR	LAR
Number of retrieved lymph nodes	11	42	17	17	0	21	13	10	11	8	24
ypT stage	3	2	0	2	2	3	4b	3	3	4b	3
ypN stage	2a	1a	0	1a	NA	1a	1b	0	2a	2b	0
RCRG	1	2	1	1	1	2	2	1	3	2	2
Resection margin	R0	R0	R0	R0	R0	R0	R0	R0	R0	R1	R0
Positive CRM (pathological)	No	No	No	No	No	No	No	No	No	Yes	No
Positive EMVI (pathological)	Yes	No	No	No	No	Yes	Unknow	Unknow	Unknow	Yes	No
Recurrence time (month)	92	23	34	23	28	7	31	23	39	13	28
Recurrence site	Anastomotic	Anastomotic	Presacral space	Anastomotic	Anastomotic	Internal iliac lymph nodes	Bladder	Anastomoticsalpingo, bladder	Bladder	Bladder, perineum, internal iliac lymph nodes	External iliac lymph nodes
Distant metastasis	No	No	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Distant metastasis time (month)	NA	NA	NA	23	NA	28	31	23	39	13	28

LAR, low anterior resection; MVR, multivisceral resection; RCRG, rectal cancer regression grade; CRM, circumferential resection margin; EMVI, extramural vascular invasion; NA, not applicable